Hydroxyacylglutathione hydrolase-like protein (HAGHL)

**Hydroxyacylglutathione hydrolase-like protein (HAGHL)** is a protein-coding enzyme predicted to function as a hydrolase acting on ester bonds, with activity similar to hydroxyacylglutathione hydrolase (also known as glyoxalase II)[1][9]. It participates in the catabolic pathway that converts methylglyoxal, a toxic metabolite, to D-lactate via S-lactoyl-glutathione, likely helping in cellular detoxification processes[1][8][9]. HAGHL is associated with several rare disorders such as glycogen storage disease IXc and congenital myopathy 4A[1]. Its expression has been profiled in normal and cancerous tissues, and it is predicted to be an intracellular enzyme containing zinc as a cofactor[2][9]. Key authoritative identifiers: - HGNC: 14177 - NCBI Gene: 84264 - UniProtKB: Q6PII5 No known direct drug interactions, clinical biomarkers, or specific safety issues are documented in major sources as of now.

Other names

MGC2605GLO2-likeRJD12hydroxyacylglutathione hydrolase-like proteinHAGHL